Literature DB >> 9606305

Slipped capital femoral epiphysis.

R T Loder1.   

Abstract

Slipped capital femoral epiphysis occurs during the adolescent growth spurt and is most frequent in obese children. Up to 40 percent of cases are bilateral. Recent classification methods emphasize epiphyseal stability rather than symptom duration. Most cases of slipped capital femoral epiphyses are stable and have a good prognosis if diagnosed early. Unstable slipped capital femoral epiphysis has a much poorer prognosis because of the high risk of avascular necrosis. Early radiographic clues are the metaphyseal blanch sign and Klein's line. Once diagnosed, treatment should begin immediately. The most widely accepted treatment for a stable slipped capital femoral epiphysis is in situ fixation with a single central screw. The treatment for an unstable slipped capital femoral epiphysis is much more controversial. Corrective osteotomy is usually reserved for treatment of severe deformities after the patient has stopped growing.

Entities:  

Mesh:

Year:  1998        PMID: 9606305

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  14 in total

1.  The gait function of slipped capital femoral epiphysis in patients after growth arrest and its correlation with the clinical outcome.

Authors:  Bettina Westhoff; Katharina Ruhe; Kristina Weimann-Stahlschmidt; Christoph Zilkens; Reinhart Willers; Rüdiger Krauspe
Journal:  Int Orthop       Date:  2011-11-24       Impact factor: 3.075

2.  MRI morphometry, cartilage damage and impaired function in the follow-up after slipped capital femoral epiphysis.

Authors:  Falk R Miese; Christoph Zilkens; Arne Holstein; Bernd Bittersohl; Patric Kröpil; Marcus Jäger; Tallal C Mamisch; Rüdiger Krauspe; Ulrich Mödder; Günther Fürst
Journal:  Skeletal Radiol       Date:  2010-02-24       Impact factor: 2.199

3.  Painful paediatric hip: frog-leg lateral view only!

Authors:  J Bomer; F Klerx-Melis; H C Holscher
Journal:  Eur Radiol       Date:  2013-10-08       Impact factor: 5.315

4.  Slipped capital femoral epiphysis (SCFE) detected in a chiropractic office: a case report.

Authors:  Peter Emary
Journal:  J Can Chiropr Assoc       Date:  2009-08

5.  Radiological outcome and gait function of SCFE patients after growth arrest.

Authors:  Bettina Westhoff; Katharina Schröder; Kristina Weimann-Stahlschmidt; Christoph Zilkens; Reinhart Willers; Rüdiger Krauspe
Journal:  J Child Orthop       Date:  2013-10-19       Impact factor: 1.548

6.  Management of Slipped Capital Femoral Epiphysis: The Hawai'i Experience.

Authors:  John P Livingstone; Mariya I Opanova; Robert C Durkin; William Burkhalter
Journal:  Hawaii J Health Soc Welf       Date:  2019-11

7.  What Is the Prevalence of Cam Deformity After Prophylactic Pinning of the Contralateral Asymptomatic Hip in Unilateral Slipped Capital Femoral Epiphysis? A 10-year Minimum Followup Study.

Authors:  Till D Lerch; Eduardo N Novais; Florian Schmaranzer; Kai Ziebarth; Simon D Steppacher; Moritz Tannast; Klaus A Siebenrock
Journal:  Clin Orthop Relat Res       Date:  2019-05       Impact factor: 4.176

8.  Silent slipped capital femoral epiphysis in overweight and obese children and adolescents.

Authors:  Martin Wabitsch; Michael Horn; Ulrich Esch; Herrmann Mayer; Anja Moss; Klaus-Peter Günther; Manfred Nelitz
Journal:  Eur J Pediatr       Date:  2012-04-29       Impact factor: 3.183

9.  A reduction in body mass index lowers risk for bilateral slipped capital femoral epiphysis.

Authors:  Adam Y Nasreddine; Benton E Heyworth; David Zurakowski; Mininder S Kocher
Journal:  Clin Orthop Relat Res       Date:  2013-07       Impact factor: 4.176

10.  Childhood cancer survivors exposed to total body irradiation are at significant risk for slipped capital femoral epiphysis during recombinant growth hormone therapy.

Authors:  Sogol Mostoufi-Moab; Elizabeth J Isaacoff; David Spiegel; Denise Gruccio; Jill P Ginsberg; Wendy Hobbie; Justine Shults; Mary B Leonard
Journal:  Pediatr Blood Cancer       Date:  2013-07-02       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.